# CJC-1295 Ipamorelin References: The Cited Literature

> CJC-1295 Ipamorelin references: the full cited literature behind every GH/IGF-1, pharmacokinetic, synergy and safety claim on this site, with DOIs and PubMed links.

Every quantitative claim on this site maps to one of these studies. DOIs and PubMed identifiers included.

## How to read this list

These are the primary sources behind the CJC-1295 Ipamorelin claims across this site, numbered to match the inline [N] markers. Studies on the single components and on GHRH-plus-GHRP synergy carry the weight; there is no entry for a trial of the fixed blend because none exists. Human studies, animal studies, in-vitro work, and authoritative statements are all flagged in each citation.

## References

[1] Teichman SL, Ferris L, Mooradian AD, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. (Human; healthy adults) https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. (Animal; rat pituitary cells and conscious swine) https://pubmed.ncbi.nlm.nih.gov/9849822/
[3] Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. (Human; 18 normal men) https://pubmed.ncbi.nlm.nih.gov/2108187/
[4] Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. (In vitro; transfected HeLa cells) https://pubmed.ncbi.nlm.nih.gov/12446584/
[5] Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. (Animal; Sprague-Dawley rats) https://pubmed.ncbi.nlm.nih.gov/15817669/
[6] Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. (Human; review of multiple trials) https://pubmed.ncbi.nlm.nih.gov/28400207/
[7] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. (Human; meta-analysis of 5 RCTs) https://pubmed.ncbi.nlm.nih.gov/41545261/
[8] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. (Human; healthy men 20-40 yr) https://pubmed.ncbi.nlm.nih.gov/17018654/
[9] Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. (Human; 13 healthy men) https://pubmed.ncbi.nlm.nih.gov/20943777/
[10] Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. (Human; 32 healthy elderly subjects) https://pubmed.ncbi.nlm.nih.gov/8954023/
[11] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. (Human; healthy young men) https://pubmed.ncbi.nlm.nih.gov/19386527/
[12] Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and Aging: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2023;108(8):1835-1874. (Human; scientific statement) https://pmc.ncbi.nlm.nih.gov/articles/PMC11491666/
[13] Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs. 1989. (In vitro; ovine pituitary somatotrophs) https://pubmed.ncbi.nlm.nih.gov/2562826/
[14] Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. (In vitro; human plasma) https://pubmed.ncbi.nlm.nih.gov/2565342/
[15] Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. 1986. (Human; healthy men) https://pubmed.ncbi.nlm.nih.gov/?term=pharmacokinetics+GRF+1-29+NH2+normal+men

---

A graphene-lab readout of the CJC-1295 and ipamorelin literature — the GH and IGF-1 numbers, the DAC-versus-Mod-GRF half-life split, and the selectivity data logged to source, with the empty space where the fixed-blend trial should be left lit on the panel; no clinic behind the console and nothing here dosed, dispensed, or sold.